Gestational Hypertension

Gestational hypertension or pregnancy-induced hypertension (PIH) is the development of new hypertension in a pregnant woman after 20 weeks’ gestation without the presence of protein in the urine or other signs of preeclampsia and eclampsia. Gestational hypertension is usually defined as having a blood pressure higher than 140/90 measured on two separate occasions, more than 6 hours apart, without the presence of protein in the urine and diagnosed after 20 weeks of gestation. There is no specific treatment, but is monitored closely to rapidly identify pre-eclampsia and its life-threatening complications.

Drug treatment options are limited, as many antihypertensive may negatively affect the fetus. Methyldopa, hydralazine, and labetalol are most commonly used for severe pregnancy hypertension. The fetus is at increased risk for a variety of life-threatening conditions, including pulmonary hypoplasia (immature lungs). If the dangerous complications appear after the fetus has reached a point of viability, even though still immature, then an early delivery may be warranted to save the lives of both mother and baby. An appropriate plan for labor and delivery includes selection of a hospital with provisions for advanced life support of newborn babies.

During gestational hypertension, a woman must be offered an integrated package of care, covering admission to hospital, treatment, measurement of blood pressure, testing for proteinuria and blood tests.

Gestational hypertension in a future pregnancy ranges from about 1 in 8 (13%) pregnancies to about 1 in 2 (53%) pregnancies.

  • Risk factors for gestational hypertension
  • Pre-eclampsia and eclampsia
  • Pathogenesis of pre-eclampsia
  • Genetic changes and stress incontinence.
  • Surgical and non-surgical conditions
  • Restorative and administration of medications
  • Drug treatment of gestational hypertension

Related Conference of Gestational Hypertension

February 19-21, 2018

23rd European Heart Disease and Heart Failure Congress

Paris, France
April 19-20, 2018

3rd World Heart Congress

Amsterdam, Netherlands
November 19-20, 2018

29th World Cardiology Conference

Edinburgh, Scotland
May 14-16, 2018

2nd World Heart Congress

Tokyo, Japan
June 11-13, 2018

24th Annual Cardiologists Conference

Barcelona, Spain
July 12-13, 2018

Global Cardiology Summit

Bangkok, Thailand
August 09-10, 2018

26th Annual Cardiology and Cardiovascular  Nursing Congress

Manila, Philippines
September 10-11, 2018

4th International Conference on Hypertension & Healthcare

Zurich, Switzerland
September 11-12, 2018

World Cardiology and Cardiologist Meeting

Stockholm, Sweden
September 14-15, 2018

4th Global Summit on Heart Diseases

Singapore
17-18 September,2018

24th World Cardiology Conference

Hong Kong
September 17-18,2018

25th Annual Cardiologists Conference

Tin Shui Wai,Hong Kong
September 21-22, 2018

27th International Conference on Clinical & Experimental Cardiology Research

Vancouver, British Columbia, Canada
September 24-26, 2018

5th World Heart and Brain conference

Abu Dhabi, UAE
October 05-06, 2018

Current and Future trends in Cardio Vascular Diseases: Research and Outcomes

Los Angeles, California, USA
October 19-20, 2018

Annual Congress on Cancer and Stem Cell Research

Baltimore, Maryland, USA
October 22-24, 2018

27th European Cardiology Conference

Rome, Italy
October 25-27, 2018

World Heart Rhythm Conference

Istanbul, Turkey
November 5-6, 2018

28thWorld Congress on Cardiology and Heart Diseases

Amsterdam, Netherlands

Gestational Hypertension Conference Speakers

Recommended Sessions

Related Journals

Are you interested in